Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- DOI
- 10.1007/s40257-026-01070-x
- Published
- 2026 Sep 25
- Container
- American journal of clinical dermatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40257-026-01070-x,
title = {Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.},
author = {King B and Soung J and Tziotzios C and Rudnicka L and Joly P and Gooderham M and Sinclair R and Mesinkovska NA and Paul C and Gong Y and Anway SD and Tran H and Wolk R and Zwillich SH and Lejeune A},
year = {2026},
journal = {American journal of clinical dermatology},
doi = {10.1007/s40257-026-01070-x},
url = {https://doi.org/10.1007/s40257-026-01070-x}
}RIS
TY - JOUR TI - Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. AU - King B AU - Soung J AU - Tziotzios C AU - Rudnicka L AU - Joly P AU - Gooderham M AU - Sinclair R AU - Mesinkovska NA AU - Paul C AU - Gong Y AU - Anway SD AU - Tran H AU - Wolk R AU - Zwillich SH AU - Lejeune A PY - 2026 JO - American journal of clinical dermatology DO - 10.1007/s40257-026-01070-x UR - https://doi.org/10.1007/s40257-026-01070-x ER -
APA
B, K., J, S., C, T., L, R., P, J., M, G., R, S., NA, M., C, P., Y, G., SD, A., H, T., R, W., SH, Z., & A, L. (2026). Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.. American journal of clinical dermatology. https://doi.org/10.1007/s40257-026-01070-x
Source records
- pubmed · retrieved 2026-09-25T23:47:09.052Z